Clinical Profile, Risk Factors and Visual Outcome of Orbital Mucormycosis in COVID-19 Patients in a Tertiary Care Hospital

Rhino orbital mucormycosis (ROCM) which is a life threatening disease has emerged as a serious problem in COVID-19 patients during the second wave. This study was conducted to analyse the various risk factors, ocular manifestations, management and the visual outcome of orbital mucormycosis in COVID-19 positive patients. This is a retrospective, record based, single centered, cross sectional study conducted in a tertiary care hospital between may2021 to October 2021. Of these 138 mucormycosis patients 89 had invasive ROCM stage 3 and 4. Among these patients 93% are diabetic, 79% were on steroids, 26% were on oxygen therapy during COVID, 13% had increased serum ferritin levels.64% patients were actively managed with intravenous injection amphotericin B, 8% of patients received retro bulbar injection amphotericin B, FESS was done in 72% patients, exenteration was done in 2% patients. A multidisciplinary approach of management was done by a team of ophthalmologist, ENT surgeon, physician, neurologist and microbiologist, in reducing the mortality and morbidity.